

IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/511,627
Applicant : Karsten Eulenberg
Filed : October 18, 2004
TC/A.U. : 1632
Examiner : Paul Thomas Dowell

Docket No. : 2923-657
Customer No. : 6449
Confirmation No. : 8622

RESPONSE TO RESTRICTION REQUIREMENT

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

June 22, 2006

Sir:

In response to the Restriction Requirement dated May 22, 2006, applicants hereby elect group X(ii), claims 25, 27 and 33, with traverse for prosecution in the present application. Applicants also elect CG7956 (synaptojanin-like protein SAC) as the polypeptide. Applicants traverse the restriction requirement on the grounds that group I(viii) should be examined together with group X(ii). Group I(viii) is directed to a pharmaceutical composition comprising a CG7956 polypeptide and thus is the composition used in the claims of group X(ii). Regarding the election of species, applicants elect diabetes as the disorder to start the prior art search.

In the event this paper is not considered to be timely filed, the Applicant respectfully petitions for an appropriate extension of time. Any fee for such an

extension together with any additional fees that may be due with respect to this paper, may be charged to Counsel's Deposit Account No. 02-2135.

Respectfully submitted,

By 

Monica Chin Kitts
Attorney for Applicants
Registration No. 36,105
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040